The mutations of KRAS, AKT1 and MAPK1 have been reported as bypass mutations which are another common mechanism of the acquired EGFR-TKI resistance that can activate the same key downstream effectors as EGFR, thereby promoting the growth and survival of tumor cells 45, 49. This evidence concerns the gene AKT1 and neoplasm.